Redhill Biopharma (RDHL) PT Raised to $30 at Roth Capital

Roth Capital analyst Scott Henry reiterated a Buy rating and boosted his price target on Redhill Biopharma (NASDAQ: RDHL) to $30.00 (from $27.50) after the company announced positive top line data this morning for RHB-105 to treat H. pylori. The eradication rate for RHB-105 of 89.4% easily topped historical controls of 70% (p<0.001).

"We upped our approval probability for RHB-105 to 75% from 50% based on this event, which increased our price target on RDHL shares to $30 (from $27.50)," Henry said.

For an analyst ratings summary and ratings history on Redhill Biopharma click here. For more ratings news on Redhill Biopharma click here.

Shares of Redhill Biopharma closed at $16.46 yesterday.

You May Also Be Interested In

• Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading
• ASM Pacific Technology (522:HK) (ASMVF) PT Raised to HK$120 at JPMorgan
• TechnipFMC (FTI) PT Raised to $30 at BTIG